# OptiTROP-Lung01 (NCT05351788)

> SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan plus tagitanlimab; sacituzumab tirumotecan plus tagitanlimab plus platinum-based chemotherapy
- Indication: advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05351788
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-small Cell Lung Cancer
- Interventions: SKB264; KL-A167; Carboplatin; Cisplatin
- Enrollment: 110
- Primary outcome: Incidence and severity of adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on OptiTROP-Lung01 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 22 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=optitrop-lung01-nct05351788

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05351788", "email": "<work email>"}; the inbox owner confirms by the emailed link.
